| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.093 | 0.01 |
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.01 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.084 | 0.01 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.074 | 0.01 |
| mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.084 | 0.01 |
| mRNA | BRD-K55116708 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.076 | 0.01 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.088 | 0.01 |